 |
Previous Article | Next Article 
The Journal of Neuroscience, August 1, 1999, 19(15):6327-6337
Pituitary Adenylate Cyclase-Activating Polypeptide Activates a
Phospholipase C-Dependent Signal Pathway in Chick Ciliary Ganglion
Neurons that Selectively Inhibits 7-Containing Nicotinic
Receptors
Desiree
Pardi and
Joseph F.
Margiotta
Department of Anatomy and Neurobiology, Medical College of Ohio,
Toledo, Ohio 43614-5804
 |
ABSTRACT |
Neuropeptide receptors couple via G-proteins to two principal
signaling pathways that elevate cAMP through adenylate cyclase (AC) or
mobilize intracellular Ca2+ through phospholipase C
(PLC)-stimulated inositol phosphate (IP) turnover and production of
inositol 1,4,5-trisphosphate (IP3). We showed
previously that high-affinity receptors for pituitary adenylate
cyclase-activating polypeptide (PACAP) are present on chick ciliary
ganglion neurons and that receptor occupation increases cAMP
production, resulting in enhanced acetylcholine sensitivity. After we
suppressed AC activity and cAMP production with 2'-5' dideoxyadenosine,
however, PACAP no longer increased acetylcholine sensitivity but
instead reduced it, suggesting that an AC-independent signal pathway
activated by PACAP inhibits some nicotinic acetylcholine receptors
(AChRs). We now use fast-perfusion, imaging, and biochemical methods to
identify the AChRs modulated by PACAP and to characterize the signal
pathway responsible for their inhibition. Without previous AC block,
both the rapidly desensitizing, -bungarotoxin ( Bgt)-sensitive 7-AChRs and the slowly desensitizing, Bgt-insensitive 3*-AChRs on the neurons were potentiated by PACAP. After AC blockade, however, PACAP inhibited 7-AChRs but left 3*-AChRs unaffected. The
selective inhibition of 7-AChRs appeared to use a PLC signaling
pathway because it was not seen after lowering PLC activity or
buffering intracellular Ca2+ and was mimicked by
dialyzing neurons with an IP3 receptor agonist. PACAP also
induced IP turnover and increased
[Ca2+]i assessed directly with
Fluo-3AM imaging. Given our previous findings that PACAP receptors
couple to AC, the present results demonstrate a remarkable ability of a
single neuropeptide to activate two signaling pathways and in so doing
selectively regulate two classes of downstream ion channel targets.
Key words:
neuropeptide; acetylcholine; ion channel; modulation; fast perfusion; Ca2+ imaging; whole-cell
recording
 |
INTRODUCTION |
Neuropeptides serve as trophic
factors, co-transmitters, and modulators of ion channel function. An
important route of neuropeptide action involves binding to a
cell-surface receptor that couples via a membrane-associated G-protein
(e.g., Gs, Gq,
Gi) to effector enzymes such as adenylate cyclase
(AC) or phospholipase C (PLC) (Ross, 1989 ; Hille, 1992 ; Exton, 1996 ).
The resulting changes in second messenger and kinase activities can
then exert potent effects on downstream targets, including ion channels
(Swope et al., 1993 ; Levitan, 1994 ). Our work has explored the
regulation of nicotinic acetylcholine receptor (AChR) channels on chick
ciliary ganglion neurons. We reported previously that AChR function is enhanced after intracellular cAMP is elevated by application of either
cAMP analogs (Margiotta et al., 1987 ) or AC-stimulating neuropeptides [vasoactive intestinal peptide (VIP) or pituitary adenylate cyclase-activating polypeptide (PACAP)] that increase endogenous cAMP production via PACAP type I receptors (Gurantz et al.,
1994 ; Margiotta and Pardi, 1995 ). To link the cAMP produced by PACAP to
subsequent AChR modulation, neurons were pretreated with AC inhibitors
(Margiotta and Pardi, 1995 ). The pretreatments blocked the ability of
PACAP to increase cAMP but, quite surprisingly, reduced the subsequent
peak ACh response below control levels. The results suggested that a
second PACAP-activated intracellular pathway inhibits AChR function,
and the present studies were undertaken to characterize this pathway
and identify the AChRs that are affected.
Ciliary ganglion neurons express two AChR classes that differ in
subunit composition, pharmacological, and electrophysiological properties. One class contains 7 subunits, which are recognized with
high affinity by -bungarotoxin ( Bgt). Membrane currents generated
by native 7-AChRs on ciliary or hippocampal neurons or by
recombinant chick or rat 7 homo-oligomers expressed in Xenopus oocytes activate and desensitize rapidly and are
blocked by Bgt (Couturier et al., 1990 ; Alkondon and Albuquerque,
1993 ; Zhang et al., 1994 ). The other AChR class on ciliary ganglion neurons ( 3*-AChRs) contains 3, 4, 5, and (sometimes) 2
subunits, but not 7 subunits, and is not recognized by Bgt
(Vernallis et al., 1993 ; Conroy and Berg, 1995 ). Whole-cell currents
generated by rapidly perfusing the neurons with 20 µM
nicotine feature two distinct components. The large, initial component
is mediated by 7-AChRs because it displays rapid onset and
desensitization kinetics and is Bgt sensitive, whereas the smaller
component is mediated by 3*-AChRs because it activates and
desensitizes more slowly and is predominantly Bgt insensitive (Zhang
et al., 1994 ; Blumenthal et al., 1999 ).
Evidence from other systems demonstrates that PACAP type I receptors
can couple to both AC and PLC (Rawlings, 1994 ). PLC-dependent signaling
would be expected to produce inositol phosphate (IP) turnover
culminating in inositol 1,4,5-trisphosphate
(IP3)-dependent mobilization of
[Ca2+]i (Hille, 1992 ). Thus the
observation that AC block unmasks an inhibition of ACh sensitivity
suggests that AC and PLC signals normally interact to achieve balanced
ACh sensitivity. The present findings confirm that PACAP type I
receptors couple to both AC- and PLC-dependent pathways and demonstrate
that the AC pathway produces PKA-dependent enhancement of both 3*-
and 7-AChRs, whereas the PLC pathway produces a
Ca2+-dependent inhibition of 7-AChRs.
A preliminary account of these results has been published previously
(Pardi and Margiotta, 1996 ).
 |
MATERIALS AND METHODS |
Cell and substrate preparation. Neurons were
dissociated from embryonic chick ciliary ganglia using collagenase A
treatment (0.3 mg/ml for 20 min at 37°C) and mechanical trituration
as described previously (Margiotta and Gurantz, 1989 ) and plated on
glass or plastic substrates coated with poly-D-lysine.
Embryonic day 13 (E13) or E14 neurons were used in most experiments
because they can be isolated with >80% recovery and express high
levels of both AChRs and PACAP type I receptors (Margiotta and Gurantz, 1989 ; Margiotta and Pardi, 1995 ). For electrophysiological and imaging
experiments, the neurons were dissociated and plated at a density of
one ganglion equivalent (~3-4 × 103
neurons) per glass coverslip (12 mm diameter) (Fisher
Scientific, Houston, TX) in the following recording solution (in
mM): 145.0 NaCl, 5.3 KCl, 5.4 CaCl2, 0.8 MgSO4, 5.6 glucose, and 5.0 HEPES, pH 7.4, containing 10% (v/v) heat-inactivated horse serum. Neurons attached to
the substrate within 30 min and were maintained at 37°C for 1-2 hr
before use. For IP turnover measurements, dissociated neurons from E12
embryos were plated on coated tissue culture wells (24 mm diameter;
Falcon) at two to six ganglion equivalents per well and maintained at
37°C in 95% air/5% CO2 in culture medium containing
myo-[3H]inositol for 16-24 hr (see
below). The culture medium consisted of MEM (no. 11090-08)
supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM glutamine, and 10% (vol/vol) heat-inactivated horse
serum (all components from Life Technologies-BRL, Rockville, MD).
To coat glass coverslips, they were first acid-washed, then treated
with poly-D-lysine in 0.13 M borate buffer, pH
8.5, washed four times with distilled water, and air-dried. For
electrophysiological experiments, 70-150 kDa poly-D-lysine
(P-0899; Sigma, St. Louis, MO) was applied to coverslips at 1 µg/ml
for 1 min (21-23°C). With this minimal coating protocol, the neuron
cell bodies became loosely attached, which allowed them to be lifted
above the substrate for agonist exposure during fast perfusion
experiments (see below). For Ca2+ imaging and IP
turnover experiments, stronger neuron attachment was achieved by
coating glass coverslips or tissue culture wells with 300 kDa
poly-D-lysine (P-1024, Sigma) at 1 mg/ml for 12-16 hr
(4°C).
Electrophysiology. Coverslips were placed in a lucite
chamber (model RC-25F, Warner Instruments, Hamden, CT) on the stage of
an Olympus CK2 inverted microscope, and the neurons were viewed with
Hoffman modulation contrast optics using a 40× (0.5 NA) long working
distance objective. The chamber volume was maintained at ~200 µl
and continuously perfused at ~2 ml/min from one of two 30 ml syringes
that contained recording solution or recording solution plus test
reagent (e.g., Bgt, PACAP, VIP) at room temperature (21-23°C).
The syringes were controlled with stopcocks and connected to the
chamber via a perfusion manifold (Model MP-4, Warner Instruments). Patch recording pipettes were pulled from Corning 8161 glass tubing [1.5 mm outer diameter (o.d.)] and had tip impedances of 1-2 M when filled with internal solution containing (in mM):
145.6 CsCl, 1.2 CaCl2, 2 EGTA, 15.4 glucose, 1 ATP,
and 5 Na-HEPES, pH 7.3. Nicotine was dissolved in recording solution
and applied by fast microperfusion (Zhang et al., 1994 ; Jonas,
1995 ) using solution streams delivered by laminar gravity flow
from the channels of glass -tubing (1.6 mm o.d.; BT-150-10,
Sutter Instruments, Novato, CA) pulled to an overall o.d. of
~100-120 µm. The -tubing was mounted to a piezoelectric device
(Burleigh Instruments, model LSS-3100) that provided rapid movement
steps and was controlled by an amplifier/driver (Burleigh Instruments,
model PZ-150M) and triggered by the recording software. To achieve fast
perfusion, an "on-cell" seal with resistance 10 G was first
formed on a loosely attached neuron, which was then gently lifted off
the substrate. A whole-cell configuration (Hamill et al., 1981 ) was then established, and the neuron was manipulated into the control recording solution stream flowing from the -tubing. After
capacitance compensation and testing for sodium currents (see below),
the stream bathing the neuron was rapidly switched to 20 µM nicotine for 3 sec and then switched back to recording
solution. With use of these devices, junction current experiments
with open tip patch pipettes containing 150 mM CsCl
reveal that movement of the interface separating streams of 150 and 75 mM NaCl occurred in <1 msec.
Neuronal responses induced by fast microperfusion with nicotine were
assessed in whole-cell mode at a holding potential
(Vh) of 70 mV as described previously
(Margiotta and Gurantz, 1989 ; Zhang et al., 1994 ). Membrane currents
were collected with an Axopatch 1B amplifier (Axon Instruments,
Burlingame, CA) and digitized using a TL-1 interface controlled by
pClamp 6.0 software (Axon Instruments). For capacity compensation,
series resistance measurement, and evaluation of sodium channels, the
currents were filtered and digitized at 10 kHz. AChR currents were
filtered at 1 kHz and digitized at 1-2 kHz. After achieving the
whole-cell configuration, membrane capacitance compensation was
achieved by eliminating the capacitive current transient in response to
a 10 mV pulse using the amplifier series resistance
(Rs) and capacitance
(Cm) controls, thereby obtaining a
measure of Rs. For most cells,
Rs was measured both before and after fast
perfusion with nicotine. Data from cells in which the average
Rs exceeded 4 M were not analyzed further.
Because Rs was usually 3 M , peak
nicotine-induced currents (approximately 7000 pA) generated a voltage
deviation (Vs) from the applied holding
potential no larger than 21 mV. In such cases, the actual holding
potential (Vh Vs = 49 mV) was well below that for
activating sodium currents (see below). Recordings were corrected for
Rs errors using one of two approaches, both of
which gave similar results. For some recordings, 60-80% compensation
was achieved with the patch-clamp controls, just before the nicotine
trial. In other cases, current values were adjusted off-line for errors
in holding potential as described previously (Margiotta and Gurantz,
1989 ), assuming an AChR reversal potential
(Er) of 11 mV. Briefly stated, each
measured current value was multiplied by a factor representing the ratio of the voltage gradient across the AChR under
conditions of zero and finite series resistance voltage error ( = (Vh Er)/(Vh Er Vs)).
Although the Rs correction allowed more accurate
measurement of individual nicotine-induced whole-cell currents, the
general conclusions presented here were not significantly changed when the results were reanalyzed without the correction. To test for adequate access, sodium currents were induced by applying a family of
test depolarizations from 40 to +30 mV in 5 mV increments. Sodium
current activation occurred in a voltage range from 25 to 0 mV. Cells
in which sodium currents activated late or displayed discontinuities in
their rising or falling phases were not studied further.
Whole-cell AChR currents induced by fast nicotine perfusion activated
rapidly to a peak value (Ip) and then
decayed with complex kinetics caused by the contribution of distinct
AChR classes having different rates of desensitization (Zhang et al.,
1994 ; Vijayaraghavan et al., 1995 ). The nicotine-induced current at
time t (It) from Ip (t = 0) was well
characterized by fitting to the data the sum of two to three
exponential functions given by It = Af exp( t/ f) + Ai exp( t/ f) + As exp( t/ f) + C using a Simplex algorithm included in pClamp.
Af, Ai, and
As indicate the amplitudes of the fast,
intermediate, and slow current components, f,
i, and s represent their
respective decay time constants, and C represents the
amplitude of the nondecaying current. The algorithm usually converged
within 103 iterations and produced fits with
associated errors <80 pA (typically <2% of
Ip). Because we were most interested here
in the fast component, its amplitude (If)
was estimated both from the fit value
(Af) and by subtracting the summed slower
component amplitudes (Is = Ai + As + C)
from the decaying peak current (Ip).
If values presented here were obtained using the
latter method and were within 10% of those obtained using the former
approach. Component current values were normalized for differences in
cell size by dividing Ip,
If, and Is values
by the membrane capacitance (Cm) determined from the patch-clamp controls. The change in agonist response for neurons in the test condition was determined by comparing normalized current amplitude values with neurons in control conditions from the same experiment. The statistical significance of any changes
(p < 0.05) was determined using Student's
unpaired t test.
Inositol phosphate release assay. The coupling of type I
PACAP receptors to IP turnover was assessed using an approach
similar to that described by Rathouz et al. (1995) . Neurons were
incubated at 37°C in culture medium containing 2 µCi/ml
myo-[3H]inositol (NEN/DuPont,
Wilmington, DE) (specific activity ~19 mCi/mmol) for 16-24 hr,
washed three times in MEM containing 50 mM LiCl, and
equilibrated a final 20 min in the same buffer at 37°C. Test peptides
were then added from frozen stocks to duplicate or quadruplicate wells,
and the cells were incubated for 50-60 min at 37°C. In some cases
neurons were preincubated for 20 min with indicated concentrations of
AC or PLC inhibitor before peptide addition. Reactions were stopped by
placing the cultures on ice, followed by addition of 0.5 vol
ice-cold methanol. Cells were scraped from the wells, the lipids were
extracted with chloroform and water (0.5:0.4, v/v), and an aliquot of
the chloroform phase was taken to determine the extent of incorporation
of label into IPs. The aqueous layer was transferred to a tube
containing 300 mg of the anion exchange resin AG-1X8 (formate form),
vortexed briefly, and incubated at room temperature for 20 min. After
rapid centrifugation, the liquid phase was removed, and an aliquot was counted in a scintillation counter to determine the amount of label
remaining as free inositol. The resin was rinsed three times with water
and then incubated for 30 min with 1 ml of ice-cold 2 M
ammonium formate/0.1 M formic acid, the tubes were
centrifuged briefly, and 10 ml of scintillation fluid was added to the
eluate for counting. Specific counts from each individual sample well for a given condition were averaged. For each peptide dose, the change
in total IPs was determined as the average of the counts in the
presence of peptide minus the average of counts in the absence of
peptide, and the data were fit by nonlinear regression using Prism
version 2.0 (GraphPad Software, San Diego, CA).
Calcium imaging. After a 1 hr incubation at 37°C, cells
were loaded with the calcium indicator dye Fluo-3AM (1 µM; Molecular Probes, Eugene, OR) (Kao et al., 1989 ) in
recording solution (see description of solutions) for 45 min at room
temperature in the dark. Cells were then washed three times with
recording solution and maintained in darkness until use. Neurons were
examined with reflected light fluorescence optics using an Olympus BX50
microscope equipped with a 40× water immersion objective (Uplan Fl
40×, 0.8 N.A.). Excitation light from a 100W mercury lamp was passed
through a 450-480 nm bandpass filter, reflected from a 500 nm dichroic mirror, and focused through the objective onto the neurons. The emitted
light passed through the objective and dichroic mirror and was observed
using a standard 515 nm barrier filter set. The bath was continuously
perfused by gravity flow at ~2 ml/min, and solutions were switched
manually between control and peptide tests just after the shutter was
opened. In some cases, neurons were clamped in whole-cell mode using
patch pipettes filled with intracellular solution containing 200 µM 2'-5' dideoxyadenosine (ddA), with or without other
test compounds. For each trial, a sequence of 12-15 eight-bit images
covering time before, during, and after application of test solutions
was captured using a cooled digital CCD camera (SENSYS; Photometrics,
Tucson AZ) under the control of IP Lab software (v 3.0 Scanalytics,
Reading, PA). For analysis and quantitation, the Fluo-3AM fluorescence
signals were corrected for variability in dye loading and path length
by normalizing to the baseline fluorescence
(F0) as described previously
(Cornell-Bell et al., 1990 ; Vijayaraghavan et al., 1992 ). The change in
fluorescence intensity ( F = F F0) relative to F0
was determined from ellipsoid regions of interest (ROIs) overlaid on
each neuron somata in a field (one to five neurons per field). As a
criterion, neurons displaying F/F0
0.15 during the 30-90 sec of peptide application were scored as
responsive. By this criterion, 85% of 67 neurons tested responded to
application of 100 nM PACAP38 with an increase in
[Ca2+]i. For other test conditions,
the sample size required for the proportion of responsive neurons to be
significantly different (p < 0.05) from 0.85 was estimated using the equation for comparing two independent
proportions (Motulsky, 1995 ), with = 0.05 and = 0.2. Digitized image frames were manipulated for presentation using
Photoshop (v 4.0.1; Adobe Systems, Inc.) after conversion to TIFF format.
Materials. Fertilized White Leghorn chicken eggs were
obtained from Hertzfeld Poultry Farm (Waterville, OH) and maintained at
37°C in a forced-air draft incubator at 100% humidity. PACAP38, PACAP27, and VIP were obtained from the American Peptide Company (San
Diego, Ca). Glucagon was obtained from Peninsula Laboratories (Belmont,
CA). Bgt, ddA, D-myo-inositol
1,4,5,-trisphosphate, 3-deoxy-, hexasodium salt
(HA-IP3), D-myo-inositol
1,4,5,-trisphosphate, 2,3,6-trideoxy-, hexasodium salt
(LA-IP3),
{N-[2-((p-bromocinnamyl)amino)ethyl]-5-isoquinolinesulfonamide, HCl} (H-89), Ruthenium Red, and
{1-[6-((17 -3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl]-1H-pyrrole-2,5-dione} (U-73122) were all purchased from Calbiochem (La Jolla, CA). All other
reagents were obtained from Sigma.
 |
RESULTS |
PACAP differentially regulates 7- and 3*-AChRs
We previously reported a dual action for PACAP on neuronal
nicotinic AChR function (Margiotta and Pardi, 1995 ). Application of the
peptide to ciliary ganglion neurons normally increased cAMP production
and subsequent ACh sensitivity but led to reduced ACh sensitivity when
the neurons were pretreated with AC inhibitors (ddA or SQ-5536) to
limit cAMP production. To identify the AChR subtypes modulated by
exposure to PACAP and to further characterize the relevant signaling
mechanisms, we incorporated fast nicotine perfusion, a method that
allows whole-cell currents activated by the two major classes of AChRs
on the neurons to be distinguished on the basis of differences in
component amplitudes and desensitization kinetics (Zhang et al., 1994 ;
Blumenthal et al., 1999 ). Neurons pretreated with ddA displayed a large
inward current in response to fast perfusion with 20 µM
nicotine that activated to peak value (Ip) within 2-5 msec and subsequently
desensitized with kinetics that could be described by the sum of two or
three exponential functions (Fig.
1A) (see Materials and
Methods). The large-amplitude initial current
(If) decayed rapidly
( f = 1-10 msec) and was accompanied by one to two
smaller components that decayed more slowly ( i = 0.1-0.4 sec; s = 0.4-12.0 sec). The fast current component of the nicotine response (If)
is likely to represent activation of 7-AChRs. Exposure to Bgt, a
toxin that specifically recognizes 7-AChRs on ciliary ganglion
neurons and blocks their function, abolished
If/Cm in all of
the 13 neurons tested (Fig. 1B), reducing
Ip/Cm by >80%.
In contrast, the slow current components are likely to primarily
represent activation of 3*-AChRs because Is/Cm was not
detectably different (p > 0.1) in 22 control
and 9 Bgt-treated neurons ( 60 ± 6 and 51 ± 5 pA/pF,
respectively). In addition, the slow current desensitization kinetics
( i, s) were not detectably
changed after exposure to Bgt (p > 0.1 for each). Thus the whole-cell fast perfusion method permits identification of currents produced by activation of 7- and 3*-AChRs, the two major nicotinic receptor classes on chick ciliary ganglion neurons.

View larger version (31K):
[in this window]
[in a new window]
|
Figure 1.
PACAP selectively inhibits 7-AChR currents when
AC activity is suppressed. A-C, Representative
whole-cell current records are displayed from separate E13 and E14
ciliary ganglion neurons held at 70 mV and exposed to 20 µM nicotine for ~3 sec by fast perfusion, as indicated
by the solid bar. All neurons were pretreated with 200 µM ddA for 1-7 min to inhibit AC as described in
Materials and Methods. Arrows labeled
If and Is
indicate peak values of the 7- and 3*-AChR current components,
respectively. Calibration bars in C apply to
A-C. A, Response to 20 µM
nicotine application from a control neuron
(Cm = 23 pF) features a rapidly
activating current reaching a peak value
(Ip) of 6121 pA and decaying with
complex kinetics. The rapidly activating and desensitizing part of the
response is shown on an expanded time scale in the
inset, showing the superimposed fit to the equation in
Materials and Methods (dots) and the associated values
of f and i ( s shown
above). Similar nicotine responses were obtained in the presence of 1 µM TTX and 10 µM CdCl2 (J. Margiotta, unpublished observations), indicating that they arise from
nicotinic AChRs rather than from voltage-dependent
Na+ or Ca2+ channels (Zhang et
al., 1994 ). B, Nicotine response from a neuron
(Cm = 28 pF) incubated with 60 nM Bgt beginning 2 hr before, and continuing throughout,
the ddA pretreatment and recording (dashed bar). Note
that the fast component is abolished by Bgt, indicating that it
arises from 7-AChRs. C, Nicotine response from a
neuron (Cm = 25 pF) treated with 100 nM PACAP38 for 6 min after the ddA pretreatment. Note that
the PACAP38 treatment reduced the 7-AChR component
(If), leaving the 3*-AChR
component (Is) unaffected.
D, Summary of the percentage change
(mean ± SEM) in the 7-AChR
(If/Cm)
and 3*-AChR
(Is/Cm)
response components after treatment with neuropeptides. Each bar is
based on nicotine responses like those in A and
C where the individual fast and slow current components
indicated by the black and gray bars,
respectively, were determined as described above for the indicated
peptide treatment (n = 6-19 for each
concentration). Results are expressed as a percentage of the component
nicotine responses obtained from the same number of control neurons
tested in parallel that were treated with ddA alone. The
bars labeled none depict results from
neurons treated with ddA alone, compared with untreated controls.
Asterisks indicate a significant change
(p < 0.05 by Student's t
test) in the relevant current component associated with the indicated
peptide treatments. Note that both PACAP38 and PACAP27 selectively
reduced the 7-AChR component without affecting the 3*-AChR
component.
|
|
Whole-cell nicotine response parameters obtained from neurons
pretreated with ddA (200 µM, 2-5 min) (Table
1) were indistinguishable from those
obtained from untreated neurons tested in parallel (Fig.
1D). When the ddA pretreatment was followed by
treatment with PACAP38 (100 nM, 10 min) to maximally occupy
PACAP type I receptors, however, the subsequent nicotine-induced
7-AChR current was reduced compared with control neurons pretreated
with ddA alone (Fig. 1, compare A, C). The
inhibition was specific for 7-AChRs because
If/Cm was
significantly reduced, whereas
Is/Cm representing
3*-AChRs was unchanged (Table 1). Percentage changes in
If/Cm for neurons
treated with high- or low-affinity type I receptor ligands relative to
ddA controls tested in parallel are compiled in Figure
1D. PACAP38 and PACAP27 significantly reduced If/Cm by similar
amounts (55 ± 10% and 40 ± 9%, respectively; p < 0.05 for both), whereas neither peptide detectably
changed the slower 3*-AChR current component
Is/Cm
(p > 0.1 for both). No significant inhibition
was observed for VIP, a low-affinity PACAP type I receptor ligand
(IC50 ~1 µM).
If/Cm was
unchanged in neurons treated with 100 nM VIP, and although
1 µM VIP produced an apparent 20% inhibition, the effect
was not statistically significant (p > 0.1;
n = 4 neurons). Neither of the VIP concentrations that was tested detectably altered
Is/Cm (Fig.
1D). PACAP38 appeared to reduce f
somewhat (Table 1); however, the kinetics of desensitization reflected
in values of f, i, and
s were not significantly altered in neurons treated with
either of the PACAPs when compared with control neurons tested in
parallel (p > 0.05 for each; n = 4-17 treated and control neurons). These findings indicate that
occupation of PACAP type I receptors by high-affinity ligands leads to
selective inhibition of 7-AChRs and suggest that the inhibition does
not involve a change in AChR desensitization.
A similar approach was used to examine the ability of PACAP to regulate
7- and 3*-AChR currents when the ddA pretreatment was omitted,
allowing AC activity to remain intact and PACAP receptor activation to
maximally stimulate cAMP production (Margiotta and Pardi, 1995 ). Under
such conditions, and in accord with previous observations (Margiotta et
al., 1987 ; Margiotta and Pardi, 1995 ), PACAP38 treatment (100 nM, 5 min) significantly increased both 7- and
3*-AChR current components of the subsequent response to 20 µM nicotine by approximately twofold (Fig.
2). In addition to involving an increase
in cAMP, the ability of PACAP to enhance both the 7- and 3*-AChR
currents is likely to require downstream activation of protein kinase A
(PKA), because 5 min preincubation with the PKA inhibitor H-89 (10 µM) blocked the increases in both If/Cm and
Is/Cm. The upregulation of 3*-
and 7-AChRs produced by PACAP in ciliary ganglion neurons is
consistent with relatively slow peptide receptor activation of a cAMP-
and PKA-dependent signaling cascade rather than with rapid AChR
modulation expected from membrane-delimited direct G-protein
interaction, as reported previously for rat intracardiac neurons
(Cuevas and Adams, 1996 ). We nevertheless tested for rapid modulatory
effects by comparing 3*- and 7-AChR responses induced by nicotine
(20 µM) plus PACAP38 (100 nM) with those
induced by nicotine alone. In such experiments, however, the 3*- and
7-AChR responses were not significantly different under the two
conditions (Fig. 3, left).
Negative results were also obtained after pretreating the neurons with
ddA (200 µM, 10 min) to block AC (Fig. 3,
right). Taken together, these findings indicate that PACAP
receptor activation leads to differential regulation of 7- and
3*-AChRs, occurring over the course of minutes, that depends on the
availability of the AC signaling pathway. PACAP enhances the function
of both 7- and 3*-AChRs when AC is active, causing cAMP to
increase and subsequently activate PKA but selectively inhibits
7-AChR function after AC activity is suppressed. We next focused on
defining the latter, cAMP-independent signaling pathway activated by
PACAP that leads to 7-AChR inhibition.

View larger version (16K):
[in this window]
[in a new window]
|
Figure 2.
When AC activity is left intact, PACAP enhances
7- and 3*-AChR currents by a mechanism requiring PKA.
Representative whole-cell currents induced by fast perfusion with 20 µM nicotine are shown from a control neuron
(A) (Cm = 29 pF)
and a neuron treated with 100 nM PACAP38 for 8 min before
testing (B) (Cm = 27 pF). Neurons were held at 70 mV and not pretreated with ddA.
Calibration bars in B apply to both records. The values
of If/Cm
( 7-AChRs) and
Is/Cm
( 3*-AChRs) were 174 and 40 pA/pF, respectively, for the neuron
in A, and 288 and 133 pA/pF, respectively, for the
neuron in B. C, Summary of 7- and
3*-AChR component responses to 20 µM nicotine
(black and gray bars, respectively) after
10 min incubation in 100 nM PACAP38 (left).
PACAP treatment enhanced both 7- and 3*-AChR currents by
approximately twofold (asterisks above
bars indicate p < 0.02). When
neurons were pretreated for 5 min with 10 µM H-89 to
inhibit PKA activity (right), however, treatment with
PACAP38 failed to change subsequent 7- or 3*-AChR components
(p > 0.1). Results were obtained for eight
neurons for each condition and are expressed as a percentage (mean ± SEM) of the 7- and 3*-AChR component nicotine responses
obtained from control neurons (exposed to neither PACAP nor H-89)
tested in parallel (dashed line).
|
|

View larger version (32K):
[in this window]
[in a new window]
|
Figure 3.
Absence of any immediate AChR modulation by PACAP.
7- and 3*-AChR responses (black and gray
bars, respectively) to 20 µM nicotine coapplied
with 100 nM PACAP38 (Nic + PACAP) are
compiled relative to responses from neurons tested in parallel that
were challenged with 20 µM nicotine alone (dashed
line). Under such conditions, PACAP38 failed to detectably
alter the AChR responses (p > 0.1 for each
bar) either when AC was left intact ( ) or after AC inhibition (+) by
10 min pretreatment with 200 µM ddA
(n = 7-10 neurons tested with Nic + PACAP or with
Nic alone for each condition).
|
|
The ability of PACAP to inhibit 7-AChR function is
Ca2+ dependent
A previous report suggested that free intracellular calcium
[Ca2+]i might play a role in
inhibiting 7-AChR function (Vijayaraghavan et al., 1995 ). We
therefore examined the involvement of
[Ca2+]i in PACAP38-mediated 7-AChR
inhibition by including BAPTA in the patch pipette to buffer
[Ca2+]i. The presence of BAPTA
specifically abolished PACAP's ability to subsequently inhibit
7-AChRs (Fig. 4). As in Figure 1 and Table 1, 7-AChR currents from ddA-pretreated/PACAP-treated neurons dialyzed with standard intracellular solution were attenuated compared
with neurons not exposed to peptide. When ddA-pretreated neurons were
dialyzed with intracellular solution containing 10 mM BAPTA
and then treated with 100 nM PACAP38, however, subsequent 7-AChR responses were indistinguishable from those obtained from neurons not exposed to PACAP38. As reported previously (Zhang et al.,
1994 ), including BAPTA in the recording pipette did not alter
nicotine-evoked currents in control neurons not exposed to ddA or PACAP
(n = 3 neurons) but did reduce Ca2+
elevation in response to application of 20 µM nicotine or
60 mM KCl (data not shown). These findings indicate that
the signaling pathway, recruited after PACAP receptor activation,
increases free [Ca2+]i as a
requirement for subsequent 7-AChR inhibition.

View larger version (34K):
[in this window]
[in a new window]
|
Figure 4.
PACAP inhibits 7-AChRs by a mechanism involving
[Ca2+]i mobilization. Ciliary ganglion
neurons were pretreated with ddA (200 µM) for 2-7 min to
block AC activity, subjected to the indicated treatments, and
subsequently tested for nicotine responses as described in the legend
for Figure 1. Control neurons received no PACAP38 treatment
(unfilled bar) and displayed 7-AChR responses
(If/Cm)
of 217 ± 18 pA/pF (n = 6). PACAP38 treatment
(100 nM, 10 min) inhibited 7-AChRs (black
bar), reducing
If/Cm in
this experiment by nearly 70% (*p < 0.001). When
the same PACAP38 treatment was preceded by dialysis with 10 mM BAPTA, however, it failed to inhibit 7-AChRs
(gray bar). Each bar represents the mean (±SEM)
7-AChR component nicotine response for each condition
(n = 6-8 neurons), expressed as a percentage of
that obtained from ddA controls from the same two experiments.
7-AChR responses obtained from three neurons dialyzed with BAPTA but
not treated with PACAP (striped bar) were not detectably
different from control neurons dialyzed with normal intracellular
solution. 3*-AChR responses were not significantly changed by the
treatments (p > 0.1; data not shown).
|
|
PACAP releases Ca2+ from an
IP3-sensitive intracellular store
Many G-protein-coupled receptors are known to increase
[Ca2+]i by stimulating PLC, thereby
initiating IP turnover that culminates in the generation of
IP3, a soluble intracellular messenger (Hille, 1992 ;
Exton, 1996 ). IP3 can then bind to a receptor on the
endoplasmic reticulum membrane, stimulating the release of calcium into
the cytoplasm (Berridge, 1993 , 1997 ). Because elevated
[Ca2+]i was required for PACAP to
inhibit 7-AChRs, the ability of PACAP38 and related peptides to
raise [Ca2+]i was tested using imaging
methods after loading the neurons with a calcium indicator dye
(Fluo-3AM). In typical experiments, the whole-cell recording
configuration was established on dye-loaded neurons using patch
pipettes filled with intracellular solution containing ddA, and the
bath then was perfused with recording solutions containing PACAP38
(Fig. 5A). Neurons loaded with
Fluo-3AM before peptide exposure displayed a pale blue-green
fluorescence associated with basal calcium levels. During bath
perfusion with 100 nM PACAP38, the fluorescence intensity
gradually increased in 85% of neurons tested (Fig. 5A,
Table 2), reaching a plateau approximately 1.5-fold above basal levels within 30-90 sec. No change
was detected in neurons exposed to recording solution lacking the
peptide (data not shown). The increased fluorescence response to
PACAP38 application was indicative of elevated
[Ca2+]i because it was absent in most
neurons dialyzed with 10 mM BAPTA to buffer
[Ca2+]i. PACAP-dependent activation of
AC was not a requirement for elevation of
[Ca2+]i levels because the proportion
of neurons responding to PACAP application was indistinguishable in
neurons dialyzed with ddA (89%, n = 9) and in adjacent
neurons not exposed to the inhibitor (84%, n = 58). In
contrast, PACAP-dependent activation of PLC was required because the
fraction of PACAP-responsive neurons was reduced to 25% when neurons
were dialyzed with U-73122 to block PLC (Basille et al., 1995 ; Barnhart
et al., 1997 ) and subsequent IP3 formation. PACAP-induced
elevation of [Ca2+]i similar to that
obtained in normal perfusion solution was observed in the absence of
added Ca2+ (Fig. 5B), indicating that the
[Ca2+]i arose from an intracellular
store. To localize the source of the Ca2+ released
by PACAP application, we examined the effects of IP3 or
ryanodine receptor blockers applied to neurons via the patch pipette.
Inclusion of heparin in the patch pipette to block IP3 receptors (Ghosh et al., 1988 ; Rawlings et al., 1994 ) reduced the
fraction of neurons responding to PACAP with a detectable increase in
[Ca2+]i to 11%, whereas Ruthenium
Red, a ryanodine receptor blocker (Kano et al., 1995 ), was without
effect (Table 2). Thus consistent with its
Ca2+-dependent ability to inhibit 7-AChRs,
imaging experiments indicate that PACAP38 mobilizes
[Ca2+]i from an
IP3-sensitive store by using a PLC-dependent signaling pathway.

View larger version (80K):
[in this window]
[in a new window]
|
Figure 5.
PACAP mobilizes intracellular
Ca2+ stores. A, Application of
PACAP38 elevates [Ca2+]i in both
ddA-dialyzed and intact ciliary ganglion neurons. A1,
Image obtained using bright-field optics that depicts a field of three
neurons bathed in normal recording solution. A whole-cell recording has
been established on the center neuron, causing its intracellular
contents to be dialyzed with pipette solution containing 200 µM ddA to inhibit AC. A2,
A3, The same field as in A1 showing
images obtained using epifluorescence optics taken 0 and 90 sec after
initiating bath perfusion with normal recording solution containing 100 nM PACAP38. Note the increased Fluo-3AM fluorescence in
each of the three neurons. B, PACAP38 elevates
[Ca2+]i in ciliary ganglion neurons
bathed in recording solution lacking added Ca2+.
B1, Bright-field optics. B2,
B3, Epifluorescence images taken 0 and 90 sec after
initiating perfusion with 0 Ca2+ recording solution
containing 100 nM PACAP38. Scale bar (shown in
B3 for all panels): 20 µm.
|
|
PACAP increases inositol phosphate turnover via PLC
We directly tested the ability of PACAP38 and related peptides to
activate the PLC-dependent signaling pathway in ciliary ganglion
neurons using IP turnover assays (Fig.
6). After 16-24 hr incubation with
3H-inositol, exposure to PACAP38 or PACAP27 caused a
dose-dependent release of 3H-IPs (Fig.
6A). Maximal 3H-IP release (approximately
two- to threefold above basal) was obtained with 100 nM
PACAP38 or PACAP27, the same concentration that inhibited 7-AChR
currents in the electrophysiological assays (Fig. 1, Table 1). Peptide
potencies were determined from the concentrations required to produce
50% of maximum 3H-IPs release (EC50).
EC50 values were 0.2 ± 0.1 nM
(n = 5) for PACAP38 and 2.4 ± 1.1 nM
(n = 3) for PACAP27. The 12-fold higher potency of
PACAP38 over PACAP27 (p < 0.02) for stimulating
IP turnover in ciliary ganglion neurons contrasts with their similar potencies for stimulating cAMP production in the neurons
(EC50 = 0.5 nM and 1.1 nM,
respectively (Margiotta and Pardi, 1995 ). Consistent with our
electrophysiological findings (Fig. 1), 100 nM VIP failed
to stimulate IP turnover and did so only marginally even when applied
at 1 µM. Glucagon, a PACAP-related peptide with low
affinity for the type I receptor, was ineffective even at 1 µM. A similar pharmacology indicative of PACAP
specificity and differential coupling of PACAP38 and PACAP27 to AC and
PLC transduction pathways is observed for native type I receptors on
PC12 cells (Deutsch and Sun, 1992 ) and for cloned type I receptors
expressed in LLC-PK1 cells (Spengler et al., 1993 ). Because of
this ability to couple to two transduction cascades, it was important
to determine the relative importance of the PLC and AC effectors for
increasing IP production. When neurons were preincubated with U-73122
to inhibit PLC and then challenged with PACAP, there was a 50%
reduction in the specific peptide-induced release of 3H-IPs
(Fig. 6B). In contrast, preincubation with ddA to
inhibit AC did not detectably alter basal or PACAP-induced release of 3H-IPs. These findings demonstrate that PACAP38 increases
IP turnover in ciliary ganglion neurons at the same concentration that
inhibits 7-AChRs and increases
[Ca2+]i levels. The similar
pharmacological profile of both the increased IP turnover and
[Ca2+]i levels indicates that PACAP
type I receptors couple via PLC to increase IP turnover and
Ca2+ release from an IP3-sensitive
internal store.

View larger version (27K):
[in this window]
[in a new window]
|
Figure 6.
PACAP increases IP turnover via PLC.
A, PACAP38 ( ) and PACAP27 ( ) stimulate IP production in a
dose-dependent manner. Ciliary ganglion neurons were incubated
overnight in media containing 2 µCi/ml
myo-[3H]inositol and then
challenged with the indicated concentrations of PACAP for 40-60 min.
Membrane lipids were then extracted, and 3H-IPs were
measured as described in Materials and Methods. For each peptide
concentration, the results are expressed as the percentage increase in
3H-IPs for treated neurons above the basal levels obtained
from untreated neurons. The assays were performed in duplicate, with
each curve representing a single experiment, and the results were
fitted to a sigmoidal dose-response curve (solid lines)
by nonlinear regression (r2 > 0.97). For the PACAP38 and PACAP27 data depicted, EC50
values representing the concentrations required for half-maximal IP
production were 0.5 and 4.2 nM, and maximal peptide-induced
3H-IP release above basal levels were 230 and 249%,
respectively. Similar results were obtained in four other experiments
with PACAP38 and in two experiments with PACAP27. VIP ( ) failed to
increase 3H-IP release at 100 nM and induced
only a nominal 20% increase (p < 0.1;
n = 3) at 1 µM, whereas 1 µM Glucagon ( ) produced no detectable change
(n = 2). B, PACAP38 couples via PLC
signaling to stimulate IP turnover. IPs were measured from neuron
cultures after preincubation with
myo-[3H]inositol and treatment with
1 µM PACAP38 as in A (gray
bars) and compared with parallel cultures treated with 1 µM PACAP38 plus 200 µM ddA or 1 µM U-73122 to block AC or PLC (black and
hatched bars), respectively. Results depicted were
obtained from quadruplicate well assays from two to three experiments
and indicate 3H-IP release (mean ± SEM) as a
percentage of that obtained after treatment with PACAP38 alone. Note
that U-73122 significantly reduced PACAP38-induced IP turnover
(*p < 0.01), whereas ddA was ineffective
(p > 0.1).
|
|
IP turnover-dependent Ca2+ release is required
for 7-AChR inhibition
We next sought to determine whether activation of the
PLC-dependent pathway producing IP turnover and
[Ca2+]i release is required for the
7-AChR inhibition produced by PACAP. This was accomplished by
dialyzing neurons with reagents that interfere with or mimic activation
of the PLC signaling pathway via the patch pipette before and during
exposure to PACAP38 (Fig. 7). To examine
a requirement for PLC, neurons were pretreated with ddA, then dialyzed
with intracellular solution containing the PLC inhibitor U-73122.
Because it prevented the PACAP-induced increase in
[Ca2+]i (Table 2), dialysis with 100 nM U-73122 also prevented PACAP38-induced inhibition of
7-AChRs. The PACAP-induced, PLC-dependent inhibition of 7-AChRs
is likely to require increased IP turnover, leading to IP3
production. Thus dialysis with a high-affinity IP3 receptor agonist (HA-IP3) mimicked the inhibition produced by
PACAP38, whereas application of a weak IP3 agonist
(LA-IP3) was ineffective in detectably changing
7-AChR currents. Further downstream, IP3-dependent Ca2+ mobilization is also important for inhibition
of 7-AChRs. Inclusion of heparin in the patch pipette (300 µM) to block the IP3 receptor-mediated increase in [Ca2+]i (Table 2) also
blocked the ability of PACAP38 to inhibit 7-AChRs whereas inclusion
of Ruthenium Red was ineffective. These findings demonstrate that
PACAP's Ca2+-dependent inhibition of 7-AChRs
involves PACAP type I receptor activation of PLC, IP turnover, and
IP3-sensitive Ca2+ release.

View larger version (39K):
[in this window]
[in a new window]
|
Figure 7.
PLC-dependent signaling is required for
PACAP38-induced inhibition of 7-AChRs. Ciliary ganglion neurons were
assayed for 7-AChR currents in response to fast perfusion with 20 µM nicotine as described in Materials and Methods and in
the legend for Figure 1. Results are expressed as a percentage
(mean ± SEM) of the 7-AChR component response
(If/Cm)
under the indicated test conditions, relative to that from
ddA-pretreated control neurons tested in parallel that were not treated
with PACAP38 (100%; dashed line). The PACAP38-induced
reduction of 7-AChR responses (black bars;
p < 0.02) was reversed by dialysis for 1-2 min
with U-73122 (100 nM; p > 0.1) or
heparin (300 µM; p > 0.1) before
PACAP38 treatment (gray bars) but was unaffected
by dialysis with Ruthenium Red (10 µM;
p < 0.002). Results for each condition were based
on measurements from six control neurons, six neurons treated with
PACAP38 alone, and six neurons treated with PACAP38 plus (+) the
indicated inhibitor. The PACAP38-induced inhibition 7-AChR responses
was mimicked by dialysis with HA-IP3 but not by LA-IP3 (each at 2 µM; hatched and unfilled
bars, respectively; n = 6 neurons for
each). *Significant difference from control neurons tested in parallel
(dashed line).
|
|
 |
DISCUSSION |
The preceding results elucidate dual signal cascades that
differentially modulate AChRs on chick ciliary ganglion neurons (Fig.
8). Previous experiments demonstrated
that PACAP type I receptors couple via increased AC activity and cAMP
production to enhance AChR function, but they also suggested a second
signaling pathway, unmasked after blocking AC, that reduced AChR
function (Margiotta and Pardi, 1995 ). The goals of the present study
were to characterize the inhibitory pathway and determine the relevant AChRs affected. We now report that PACAP type I receptors on the neurons also couple to a parallel PLC-dependent signaling pathway involving IP turnover and IP3-stimulated
Ca2+ release that inhibits 7-AChRs without
detectably affecting 3*-AChRs. Supportive evidence for these
conclusions emerges from three interdependent sets of experiments.
First, electrophysiological studies demonstrated that PACAP reduced
7-AChR currents when AC was suppressed. Second, biochemical and
Ca2+ imaging experiments revealed that PACAP
activates the PLC pathway, eliciting PLC-dependent IP turnover,
IP3 production, and Ca2+ release from an
IP3-sensitive store. Third, pharmacological experiments demonstrated that reagents that interfere with the PLC cascade block
the ability of PACAP to inhibit 7-AChRs.

View larger version (19K):
[in this window]
[in a new window]
|
Figure 8.
PACAP type I receptors couple through AC- or
PLC-dependent signaling cascades to differentially regulate 7- and
3*-AChR function. See Results for details.
|
|
Interpreting the electrophysiological results depended on assigning
currents induced by fast nicotine perfusion to either 7- or
3*-AChRs. The appropriateness of such assignments has already been
established (Zhang et al., 1994 ; Blumenthal et al., 1999 ) but warrants
brief discussion. First, the fitted 7- and 3*-AChR current
amplitudes (If and
Is) and associated decay time constants
( f, i, and
s) obtained in the present study (Fig. 1, Table
1) are in good agreement with those previously reported for the same
neurons (Zhang et al., 1994 ). Second, the initial fast 7-AChR
component was independently identified because
If was selectively abolished by Bgt (Fig.
1B). Third, the smaller, more slowly decaying current
component (Is) was insensitive to Bgt
and therefore unlikely to represent a contribution from 7-AChRs in
significant numbers. After identifying If and
Is as arising primarily from 7- and
3*-AChRs, respectively, we observed differential effects on the
7- or 3*-AChRs after PACAP receptor occupation that depended on
the status of the AC signaling pathway. Because PACAP type I receptors
activate two signal cascades in other systems (Rawlings, 1994 ), the
selective inhibition of 7-AChRs (Fig. 1) was presumed to result from
unmasked activation of another signal cascade, possibly one requiring
PLC. This hypothesis was initially supported by observations that ddA
blocks AC-dependent production of cAMP (Margiotta and Pardi, 1995 ) and
that without ddA pretreatment, PACAP enhances 7- and 3*-AChR
currents in a PKA-dependent manner (Fig. 2). Further support emerged by
documenting a PLC-dependent pathway in the neurons required for
PACAP-induced 7-AChR inhibition.
We showed previously that ciliary ganglion neurons express PACAP type I
receptors that stimulate cAMP production (Margiotta and Pardi, 1995 ).
The receptors have nanomolar affinities for PACAP38 and PACAP27 and
500- to 1000-fold lower affinity for VIP. The same ligands displayed
potencies for stimulating cAMP production that paralleled their
relative affinities. Studies with recombinant PACAP receptors have
demonstrated that type I receptor isoforms, featuring seven
membrane-spanning domains characteristic of G-protein-coupled receptors, can activate PLC-dependent (for review, see Spengler et al.,
1993 ; Rawlings, 1994 ) as well as AC-dependent (Hashimoto et al., 1993 ;
Pisegna and Wank, 1993 ) signal cascades. Other G-protein-coupled receptors such as those for calcitonin, parathyroid hormone, and thyrotropin are known to activate both AC and PLC cascades (for review,
see Deutsch and Sun, 1992 ; Spengler et al., 1993 ). PACAP receptors on
ciliary ganglion neurons also couple through PLC, because high-affinity
PACAP receptor ligands induced [Ca2+]i
mobilization (Fig. 5) and IP turnover (Fig. 6) even with AC activity
blocked. PACAP38, PACAP27, and VIP had potencies for IP production
(EC50 = 0.2, 2.4, 1000 nM,
respectively) that were comparable to those obtained previously for
recombinant type I receptors expressed in cell lines (Spengler et al.,
1993 ; Rawlings, 1994 ) and native PACAP type I receptors on PC12 cells
(Deutsch and Sun, 1992 ). We presume that the lower potency of PACAP27
in stimulating IP production was not reflected in our
electrophysiological assays using PACAP38 or PACAP27 because the 100 nM concentrations used produced maximal IP turnover in both cases.
In the present experiments, VIP (1 µM) did not
significantly inhibit 7-AChRs (Fig. 1) or stimulate IP turnover
(Fig. 6), although this concentration occupies ~50% of the type I
receptors on the neurons and stimulates substantial cAMP production
(Margiotta and Pardi, 1995 ). The negligible potency of VIP in
stimulating IP production is consistent with results from native and
recombinant PACAP type I receptors cited above. In such cases, the
low-affinity VIP binding to PACAP type I receptors might be inadequate
to provide sufficient activation of PLC. Our previous finding that,
after ddA pretreatment, 1 µM VIP reduced total ACh
sensitivity by 50% (Margiotta and Pardi, 1995 ) contrasts with its
nominal 20% inhibition of 7-AChRs seen here. The difference in
results is likely to be quantitative and reflect both the different
agonists and application methods used and the marginal ability of VIP
to activate PLC. In accord with the ability of PACAP38 to activate a
PLC cascade in ciliary ganglion neurons, application of the peptide
also led to increased [Ca2+]i levels
assessed by direct imaging (Table 2). The
[Ca2+]i mobilization was verified as
originating from an intracellular store because it persisted with no
added Ca2+ in the extracellular solution. As
expected for a response arising from IP turnover and subsequent
IP3 production, the
[Ca2+]i store was verified to be
IP3 sensitive because heparin, a classic IP3
receptor antagonist, blocked the response, whereas Ruthenium Red, a
ryanodine receptor antagonist, did not. In addition, the ability of
PACAP38 to increase IP turnover and
[Ca2+]i levels in the neurons was
specific to the PLC signal pathway because PLC inhibition reduced
peptide-induced IP and Ca2+ production, whereas AC
inhibition was ineffective (Figs. 5, 6). Taken together, the simplest
scheme that can explain our findings is that PACAP receptors on ciliary
ganglion neurons belong to a single type I class that can couple to
both AC and PLC signaling pathways (Fig. 8).
If a PLC-dependent signal cascade were required for 7-AChR
inhibition, then reagents applied via the patch pipette that perturb critical elements or products of the cascade should block the inhibition. All of the tests we performed satisfied this prediction, and support the proposed scheme depicted in Figure 8. First, reducing PLC activity with U-73122 blocked the ability of PACAP38 to not only
raise [Ca2+]i but also to inhibit
7-AChRs. Second, the production of IP3 was critical
because HA-IP3 mimicked the PACAP-induced inhibition of
7-AChRs, whereas the low-affinity IP3 receptor analog
(LA-IP3) was without effect. Third,
IP3-sensitive Ca2+ release was critical
because dialysis with heparin blocked both PACAP-induced increase in
[Ca2+]i and resultant inhibition of
7-AChRs. Last, the [Ca2+]i that is
produced is required because chelating Ca2+ with
application of BAPTA abolished PACAP's subsequent ability to inhibit
7-AChRs (Fig. 4). Taken together, these results strongly support the
hypothesis that the PLC pathway activated by PACAP inhibits 7-AChRs
by a process requiring Ca2+ release from an
IP3-dependent intracellular store.
How the PACAP-induced increase in
[Ca2+]i might inhibit 7-AChR
function is still an open question. A direct
[Ca2+]i effect on 7-AChRs, however,
such as that implicated for M-type K+ channels
(Selyanko and Brown, 1996 ), seems unlikely. Although previous studies
showed that increasing extracellular Ca2+ inhibits
neuronal AChRs, the effect does not involve a concomitant increase in
[Ca2+]i (Amador and Dani, 1995 ). In
addition, elevating [Ca2+]i in
neuron-like chromaffin cells by depolarization did not reduce subsequent nicotinic AChR currents (Khiroug et al., 1998 ). Thus explanations for the selective inhibition of 7-AChRs are likely to
involve indirect Ca2+-dependent mechanisms. One
possibility is that increased [Ca2+]i
enhances the activity of phospholipase A2, a
Ca2+-dependent enzyme (Kennedy, 1989 ; Mayer and
Marshall, 1993 ), causing release of arachidonic acid (AA), which in
turn inhibits 7-AChRs. Others have demonstrated that PACAP
potentiates the release of glutamate-induced AA from cortical neurons
(Stella and Magistretti, 1996 ). In addition AA (1 µM)
inhibited both native 7-AChRs on ciliary ganglion neurons and
recombinant 7-AChRs expressed in Xenopus oocytes
(Vijayaraghavan et al., 1995 ). Interestingly, the AA effect on ciliary
ganglion neurons was specific for 7-AChRs because high
concentrations were required to detectably inhibit a3*-AChRs. Another
possibility may involve activation of a
Ca2+-dependent phosphatase. One candidate is
calcineurin, which antagonizes the effects of elevations in cAMP
(Kurosawa, 1994 ) by facilitating the dephosphorylation of proteins
phosphorylated by PKA (Yakel, 1997 ). Because 7- and 3*-AChRs are
likely to be substrates for PKA-dependent phosphorylation
(Vijayaraghavan et al., 1990 ; Moss et al., 1996 ) and their upregulation
by cAMP is dependent on PKA activity (Fig. 2), 7-AChR inhibition
could involve selective dephosphorylation by a
Ca2+-dependent phosphatase.
Under normal conditions when PACAP type I receptors can couple to both
PLC and AC, cAMP production is increased in the neurons, and both 7-
and 3*-AChR currents are enhanced by a process requiring PKA (Figs.
2, 8). Whether the modulation is explained by PKA-dependent phosphorylation of AChRs alone, however, or requires additional intermediary steps and/or phosphorylation events still remains to be
determined. Because PACAP38 is approximately equipotent for stimulating
cAMP production and IP turnover in the neurons, the bias toward AChR
enhancement via AC is not likely to involve second messenger production
but instead may result from different abilities of the activated
cascades to influence their downstream targets. Overall, the results
demonstrate a remarkable flexibility in ciliary ganglion neurons for
differentially modulating two AChR classes. At one level, the findings
are consistent with PACAP's PLC-dependent dampening of 7-AChR
responses being a safety mechanism to counteract the 7- and
3*-AChR enhancement produced by concomitant AC activity. Other
scenarios are also possible, however. For example, more selective
inhibition of 7-AChRs could be achieved if the G-proteins presumed
to couple PACAP type I receptors to their AC and PLC cascades were
localized at 3*- versus 7-AChR synaptic sites, respectively, or
if receptors for other neuropeptides were present on the neurons that
couple specifically with the PLC cascade. Future efforts will be
directed toward answering such questions.
 |
FOOTNOTES |
Received Feb. 2, 1999; revised May 10, 1999; accepted May 17, 1999.
This work was supported by National Institutes of Health Grant NS24417
to J.F.M. Special thanks go to Dr. Diomedes Logothetis for support and
advice. We also thank Min Chen for expert technical assistance, and
Drs. Joan Brown, Kathleen Dunlap, Marthe Howard, Victor May, and
Phyllis Pugh for helpful discussions.
Correspondence should be addressed to Dr. Joseph Margiotta, Department
of Anatomy and Neurobiology, Medical College of Ohio, 3035 Arlington
Avenue, Toledo, OH 43614-5804.
Dr. Pardi's present address: Department of Medicine, Mount Sinai
School of Medicine, 1 Gustave Levy Place, New York, NY 10029.
 |
REFERENCES |
-
Alkondon M,
Albuquerque EX
(1993)
Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. I. Pharmacological and functional evidence for distinct structural subtypes.
J Pharmacol Exp Ther
265:1455-1473[Abstract/Free Full Text].
-
Amador M,
Dani JA
(1995)
Mechanism for modulation of nicotinic acetylcholine receptors that can influence synaptic transmission.
J Neurosci
15:4525-4532[Abstract].
-
Barnhart DC,
Sarosi GA,
Mullholland MW
(1997)
PACAP-38 causes phospholipase C-dependent calcium signaling in rat acinar cell line.
Surgery
122:465-475[Web of Science][Medline].
-
Basille M,
Gonzalez BJ,
Desrues L,
Demas M,
Fournier A,
Vaudry H
(1995)
Pituitary adenylate cyclase-activating polypeptide (PACAP) stimulates adenylate cyclase and PLC activity in rat cerebellar neuroblasts.
J Neurochem
65:1318-1324[Web of Science][Medline].
-
Berridge MJ
(1993)
Inositol triphosphate and calcium signaling.
Nature
361:315-326[Medline].
-
Berridge MJ
(1997)
Elementary and global aspects of calcium signaling.
J Physiol (Lond)
499:291-306[Free Full Text].
-
Blumenthal EM,
Shoop RD,
Berg DK
(1999)
Developmental changes in the nicotinic responses of ciliary ganglion neurons.
J Neurophysiol
81:111-120[Abstract/Free Full Text].
-
Conroy WG,
Berg DK
(1995)
Neurons can maintain multiple classes of nicotinic acetylcholine receptors distinguished by different subunit compositions.
J Biol Chem
270:4424-4431[Abstract/Free Full Text].
-
Cornell-Bell A,
Finkbeiner S,
Cooper M,
Smith S
(1990)
Glutamate induces calcium waves in cultured astrocytes: long-range glial signaling.
Science
247:470-473[Abstract/Free Full Text].
-
Couturier S,
Bertrand D,
Matter J-M,
Hernandez M-C,
Bertrand S,
Millar N,
Valera S,
Barkas T,
Ballivet M
(1990)
A neuronal nicotinic acetylcholine receptor subunit (
7) is developmentally regulated and forms a homo-oligomeric channel blocked by -Btx.
Neuron
5:847-496[Web of Science][Medline]. -
Cuevas J,
Adams D
(1996)
VIP modulation of nAChR channels in rat intracardiac neurons.
J Physiol (Lond)
493:503-515[Abstract/Free Full Text].
-
Deutsch PJ,
Sun Y
(1992)
The 38-amino acid form of pituitary adenylate cyclase-activating polypeptide stimulates dual signaling cascades in PC12 cells and promotes neurite outgrowth.
J Biol Chem
267:5108-5113[Abstract/Free Full Text].
-
Exton JH
(1996)
Regulation of phosphoinositide phospholipases by hormones, neurotransmitters, and other agonists linked to G-proteins.
Annu Rev Pharmacol Toxicol
36:481-509[Web of Science][Medline].
-
Ghosh TK,
Eis PS,
Mullaney JM,
Ebert CL,
Gill DL
(1988)
Competitive, reversible and potent antagonism of inositol 1,4,5-triphosphate-activated calcium release by heparin.
J Biol Chem
263:11075-11079[Abstract/Free Full Text].
-
Gurantz D,
Harootunian AT,
Tsien RY,
Dionne VE,
Margiotta JF
(1994)
VIP modulates neuronal nicotinic acetylcholine receptor function by a cyclic AMP-dependent mechanism.
J Neurosci
14:3540-3547[Abstract].
-
Hamill OP,
Marty A,
Neher E,
Sakmann B,
Sigworth FJ
(1981)
Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches.
Pflügers Arch
391:85-100[Web of Science][Medline].
-
Hashimoto H,
Ishihara T,
Shigemoto R,
Mori K,
Nagata S
(1993)
Molecular cloning and tissue distribution of a receptor for pituitary adenylate cyclase-activating polypeptide.
Neuron
11:333-342[Web of Science][Medline].
-
Hille B
(1992)
G protein-coupled mechanisms and nervous signaling.
Neuron
9:187-195[Web of Science][Medline].
-
Jonas P
(1995)
Fast application of agonists to isolated membrane patches.
In: Single channel recording (Sakmann B,
Necher E,
eds). New York: Plenum.
-
Kano M,
Garaschuk O,
Verkhratsky A,
Konnerth A
(1995)
Ryanodine receptor-mediated intracellular calcium release in rat cerebellar Purkinje neurons.
J Physiol (Lond)
487.1:1-16[Abstract/Free Full Text].
-
Kao JPY,
Harootunian AT,
Tsien RY
(1989)
Photochemically generated cytosolic calcium pulses and their detection by Fluo-3.
J Biochem
264:8179-8184.
-
Kennedy M
(1989)
Regulation of neuronal function by calcium.
Trends Neurosci
112:417-420.
-
Khiroug L,
Sokolova E,
Giniatullin R,
Afzalov R,
Nistri A
(1998)
Recovery from desensitization of neuronal nicotinic acetylcholine receptors of rat chromaffin cells is modulated by intracellular calcium through distinct second messengers.
J Neurosci
18:2458-2466[Abstract/Free Full Text].
-
Kurosawa M
(1994)
Phosphorylation and dephosphorylation of proteins in regulating cellular function.
J Pharmacol Toxicol Methods
31:135-139[Web of Science][Medline].
-
Levitan IB
(1994)
Modulation of ion channels by protein phosphorylation and dephosphorylation.
Annu Rev Physiol
56:193-212[Web of Science][Medline].
-
Margiotta JF,
Gurantz D
(1989)
Changes in the number, function and regulation of nicotinic acetylcholine receptors during neuronal development.
Dev Biol
135:326-399[Web of Science][Medline].
-
Margiotta JF,
Pardi D
(1995)
Pituitary adenylate cyclase-activating polypeptide type I receptors mediate cyclic AMP-dependent enhancement of neuronal acetylcholine sensitivity.
Mol Pharmacol
48:63-71[Abstract].
-
Margiotta JF,
Berg DK,
Dionne VE
(1987)
Cyclic AMP regulates the proportion of functional acetylcholine receptors on chick ciliary ganglion neurons.
Proc Natl Acad Sci USA
84:8155-8159[Abstract/Free Full Text].
-
Mayer RJ,
Marshall LA
(1993)
New insights on mammalian phospholipase A2: comparison of arachidonoyl-selective and nonselective enzymes.
FASEB J
7:339-348[Abstract].
-
Moss SJ,
McDonald BJ,
Rudhard Y,
Schoepfer R
(1996)
Phosphorylation of the predicted major intracellular domains of the rat and chick nicotinic a7 subunit by cAMP-dependent protein kinase.
Neuropharmacology
35:1023-1028[Web of Science][Medline].
-
Motulsky H
(1995)
In: Intuitive Biostatistics. New York: Oxford.
-
Pardi D,
Margiotta JF
(1996)
PACAP receptor activation inhibits
7-containing neuronal acetylcholine receptors.
Soc Neurosci Abstr
22:1522. -
Pisegna JR,
Wank SA
(1993)
Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor.
Proc Natl Acad Sci USA
90:6345-6349[Abstract/Free Full Text].
-
Rathouz MM,
Vijayaraghavan S,
Berg DK
(1995)
Acetylcholine differentially affects intracellular calcium via nicotinic and muscarinic receptors on the same population of neurons.
J Biol Chem
270:14366-14375[Abstract/Free Full Text].
-
Rawlings SR
(1994)
At the cutting edge: PACAP, PACAP receptors and intracellular signaling.
Mol Cell Endocrinol
101:C5-C9[Web of Science][Medline].
-
Rawlings SR,
Demaurex N,
Schlegel W
(1994)
Pituitary adenylate cyclase-activating polypeptide increases [Ca2+]i in rat gonadotrophs through an inositol triphosphate-dependent mechanism.
J Biol Chem
269:5680-5686[Abstract/Free Full Text].
-
Ross EM
(1989)
Signal sorting and amplification through G-protein coupled receptors.
Neuron
3:141-152[Web of Science][Medline].
-
Selyanko AA,
Brown DA
(1996)
Intracellular calcium directly inhibits potassium M channels in excised membrane patches from rat sympathetic neurons.
Neuron
16:151-162[Web of Science][Medline].
-
Spengler D,
Waeber C,
Pantaloni C,
Holsboer F,
Bockaert J,
Seeburg P,
Journot L
(1993)
Differential signal transduction by five splice variants of the PACAP receptor.
Nature
365:170-175[Medline].
-
Stella N,
Magistretti PJ
(1996)
Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) potentiate the glutamate-evoked release of arachidonic acid from mouse cortical neurons.
J Biol Chem
271:23705-23710[Abstract/Free Full Text].
-
Swope SL,
Moss SJ,
Blackstone CD,
Huganir RL
(1993)
Phosphorylation of ligand-gated ion channels: a possible mode of synaptic plasticity.
FASEB J
6:2514-2523[Abstract].
-
Vernallis AB,
Conroy WG,
Berg DK
(1993)
Neurons assemble AChRs with as many as 3 kinds of subunits while maintaining subunit segregation among subtypes.
Neuron
10:451-464[Web of Science][Medline].
-
Vijayaraghavan D,
Schmid HA,
Halvorsen SW,
Berg DK
(1990)
Cyclic AMP-dependent phosphorylation of a neuronal acetylcholine receptor
-type subunit.
J Neurosci
10:3255-3262[Abstract]. -
Vijayaraghavan S,
Pugh PC,
Zhang Z-W,
Rathouz MM,
Berg DK
(1992)
Nicotinic receptors that bind
-bungarotoxin on neurons raise intracellular free Ca2+.
Neuron
8:353-362[Web of Science][Medline]. -
Vijayaraghavan S,
Huang B,
Blumenthal EM,
Berg DK
(1995)
Arachidonic acid as a possible negative feedback inhibitor of nicotinic acetylcholine receptors on neurons.
J Neurosci
15:3679-3687[Abstract].
-
Yakel JL
(1997)
Calcineurin regulation of synaptic function: from ion channels to transmitter release and gene expression.
Trends Pharmacol Sci
18:124-134[Medline].
-
Zhang Z-W,
Vijayaraghavan S,
Berg DK
(1994)
Neuronal acetylcholine receptors that bind a-bungarotoxin with high affinity function as ligand-gated ion channels.
Neuron
12:167-177[Web of Science][Medline].
Copyright © 1999 Society for Neuroscience 0270-6474/99/19156327-11$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
H. Fischer, D.-M. Liu, A. Lee, J. C. Harries, and D. J. Adams
Selective Modulation of Neuronal Nicotinic Acetylcholine Receptor Channel Subunits by Go-Protein Subunits
J. Neurosci.,
April 6, 2005;
25(14):
3571 - 3577.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Zhou, Q. Nai, M. Chen, J. D. Dittus, M. J. Howard, and J. F. Margiotta
Brain-Derived Neurotrophic Factor and trkB Signaling in Parasympathetic Neurons: Relevance to Regulating {alpha}7-Containing Nicotinic Receptors and Synaptic Function
J. Neurosci.,
May 5, 2004;
24(18):
4340 - 4350.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Nai, J. M. McIntosh, and J. F. Margiotta
Relating Neuronal Nicotinic Acetylcholine Receptor Subtypes Defined by Subunit Composition and Channel Function
Mol. Pharmacol.,
February 1, 2003;
63(2):
311 - 324.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. G. Conroy, Q.-S. Liu, Q. Nai, J. F. Margiotta, and D. K. Berg
Potentiation of alpha 7-Containing Nicotinic Acetylcholine Receptors by Select Albumins
Mol. Pharmacol.,
February 1, 2003;
63(2):
419 - 428.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Du and L. W. Role
Differential Modulation of Nicotinic Acetylcholine Receptor Subtypes and Synaptic Transmission in Chick Sympathetic Ganglia by PGE2
J Neurophysiol,
June 1, 2001;
85(6):
2498 - 2508.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E. McNerney, D. Pardi, P. C. Pugh, Q. Nai, and J. F. Margiotta
Expression and Channel Properties of alpha -Bungarotoxin-Sensitive Acetylcholine Receptors on Chick Ciliary and Choroid Neurons
J Neurophysiol,
September 1, 2000;
84(3):
1314 - 1329.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|